221 related articles for article (PubMed ID: 22870290)
1. Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.
Tang Y; Ho G; Li Y; Hall MA; Hills RL; Black SC; Liang Y; Demarest KT
PLoS One; 2012; 7(8):e42134. PubMed ID: 22870290
[TBL] [Abstract][Full Text] [Related]
2. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.
Yu XX; Watts LM; Manchem VP; Chakravarty K; Monia BP; McCaleb ML; Bhanot S
PLoS One; 2013; 8(7):e66923. PubMed ID: 23922646
[TBL] [Abstract][Full Text] [Related]
3. CB
Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
Elife; 2020 Nov; 9():. PubMed ID: 33210603
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity.
Wei LW; Yuan ZQ; Zhao MD; Gu CW; Han JH; Fu L
Biochemistry (Mosc); 2018 Oct; 83(10):1279-1287. PubMed ID: 30472964
[TBL] [Abstract][Full Text] [Related]
5. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
[TBL] [Abstract][Full Text] [Related]
6. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L
Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336
[TBL] [Abstract][Full Text] [Related]
7. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
[TBL] [Abstract][Full Text] [Related]
8. Danning tablets alleviate high fat diet-induced obesity and fatty liver in mice via modulating SREBP pathway.
Ma Y; Li J; Ju Z; Huang W; Wang Z; Yang L; Ding L
J Ethnopharmacol; 2021 Oct; 279():114320. PubMed ID: 34116189
[TBL] [Abstract][Full Text] [Related]
9. Altered endocannabinoid signalling after a high-fat diet in Apoe(-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance.
Bartelt A; Orlando P; Mele C; Ligresti A; Toedter K; Scheja L; Heeren J; Di Marzo V
Diabetologia; 2011 Nov; 54(11):2900-10. PubMed ID: 21847582
[TBL] [Abstract][Full Text] [Related]
10. Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression.
Yu XX; Pandey SK; Booten SL; Murray SF; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E530-9. PubMed ID: 18198353
[TBL] [Abstract][Full Text] [Related]
11. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
12. Reversion of steatosis by SREBP-1c antisense oligonucleotide did not improve hepatic insulin action in diet-induced obesity mice.
Vitto MF; Luz G; Luciano TF; Marques SO; Souza DR; Pinho RA; Lira FS; Cintra DE; De Souza CT
Horm Metab Res; 2012 Nov; 44(12):885-90. PubMed ID: 22932913
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
14. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice.
Yu XX; Murray SF; Watts L; Booten SL; Tokorcheck J; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E436-45. PubMed ID: 18523126
[TBL] [Abstract][Full Text] [Related]
15. Diet-induced obese mice are leptin insufficient after weight reduction.
Shi H; Akunuru S; Bierman JC; Hodge KM; Mitchell MC; Foster MT; Seeley RJ; Reizes O
Obesity (Silver Spring); 2009 Sep; 17(9):1702-9. PubMed ID: 19373220
[TBL] [Abstract][Full Text] [Related]
16.
Lee HA; Cho JH; Afinanisa Q; An GH; Han JG; Kang HJ; Choi SH; Seong HA
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33142995
[No Abstract] [Full Text] [Related]
17. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.
Osei-Hyiaman D; Liu J; Zhou L; Godlewski G; Harvey-White J; Jeong WI; Bátkai S; Marsicano G; Lutz B; Buettner C; Kunos G
J Clin Invest; 2008 Sep; 118(9):3160-9. PubMed ID: 18677409
[TBL] [Abstract][Full Text] [Related]
18. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.
Bell-Anderson KS; Aouad L; Williams H; Sanz FR; Phuyal J; Larter CZ; Farrell GC; Caterson ID
Int J Obes (Lond); 2011 Dec; 35(12):1539-48. PubMed ID: 21386801
[TBL] [Abstract][Full Text] [Related]
19. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
Raichur S; Brunner B; Bielohuby M; Hansen G; Pfenninger A; Wang B; Bruning JC; Larsen PJ; Tennagels N
Mol Metab; 2019 Mar; 21():36-50. PubMed ID: 30655217
[TBL] [Abstract][Full Text] [Related]
20. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
